 |
|
|
 |
Measuring Preference Weights for American College of Rheumatology Response Criteria for Patients with Rheumatoid Arthritis
CHIUN-FANG CHIOU, MICHAEL WEISMAN, CATHY D. SHERBOURNE, CAROLINA REYES, MICHELLE DYLAN, JOSHUA OFMAN, DANIEL J. WALLACE, WESLEY MIZUTANI, and MARIA E. SUAREZ-ALMAZOR
ABSTRACT. Methods. A survey was mailed to 748 patients with RA from southern California. In addition to several questionnaires commonly used for patients with RA, patients were instructed to evaluate 10 hypothetical health states, in which they could have an ACR response and/or adverse events due to new treatments, with a visual analog scale (VAS). Patients also evaluated their current health with a VAS question and a time tradeoff (TTO) question. Linear extrapolation was used to derive 6 more health states. The Pearson correlation coefficient was used to validate VAS and TTO results. Results. A total of 487 (65%) patients returned the survey. Among the 10 health states evaluated with VAS directly, the health state in which a patient has ACR70 with no adverse events had the highest VAS weight (0.84), followed by the one having an ACR50 response with no adverse events (0.80). Correlation coefficients ranged from 0.63 for the correlation between VAS and physical component summary to –0.18 between TTO and pain and tender joint count; the correlation coefficients were all statistically significant, indicating there was convergent validity of the VAS and that VAS functioned differently from TTO in how it measured weights. Conclusion. VAS weights for 16 ACR response health states of patients with RA were derived. These weights could be used for cost-utility analyses of interventions for patients with RA. (J Rheumatol 2005;32:2326-9) Key Indexing Terms:
RHEUMATOID ARTHRITIS
From Cerner Health Insights, Beverly Hills; Department of Medicine, Cedars-Sinai Health System, Los Angeles; Department of Rheumatology, Cedars-Sinai Health System, Los Angeles; Health Program, Rand Corporation, Santa Monica; Pharmacoeconomics, Amgen, Thousand Oaks; Talbert Medical Group, Huntington Beach, California; Health Services Research, Baylor College of Medicine, Houston; and Houston Veteran Affairs Medical Center, Houston, Texas, USA. Supported by a grant from Amgen, Inc., Thousand Oaks, California. C-F. Chiou, PhD, Cerner Health Insights, Department of Medicine, Cedars-Sinai Health System; M. Weisman, MD, Departments of Medicine and Rheumatology, Cedars-Sinai Health System; C.D. Sherbourne, PhD, Rand Corporation; C. Reyes, PhD; M. Dylan, PhD, Cerner Health Insights; J. Ofman, MD, MSHS, Amgen, Inc.; D.J. Wallace, MD, Departments of Medicine and Rheumatology, Cedars-Sinai Health System; W. Mizutani, MD, Talbert Medical Group; M.E. Suarez-Almazor, MD, PhD, Health Services Research, Baylor College of Medicine, Houston Veteran Affairs Medical Center. Address reprint requests to M. Dylan, Cerner Health Insights, 9100 Wilshire Blvd., Suite 655E, Beverly Hills, CA 90212, E-mail: mdylan@cerner.com Accepted for publication June 3, 2005. |